Our Calls

Collaborative Laboratory to foster Translation and Drug Discovery

AccelBio Open Call 2026

Deadline Extension – AccelBio Open Call 2026

New Submission Deadline
May 2nd (14:00 GMT)
Set your drug discovery project in the right direction and turn it into an asset ready for industry.
Application Period
Until 15 Jan. 2027
Feasibility Assessment
16-31 Jan. 2027
Remote Evaluation
Early Feb. 2027
Interviews
Late Feb. 2027
Results
March 2027
Start of the project
1 April 2027

On November 4th, 2026, BIO-RED held its first Cross-Regional Showcase, “Ideas Without Borders”, an online event bringing together innovators, investors, and ecosystem stakeholders from across Europe to explore how cross-regional collaboration can turn ideas into opportunities. As a BIO-RED partner, AccelBio supported the event alongside the other partners from the project’s seven regions.

The showcase was organised together with BIO-RED’s sister project, HELIX, a health data ecosystem. After a welcome from BIO-RED Project Manager Beatriz Pereira, the programme presented BIO-RED and the opportunities it offers to participating teams, followed by an introduction to the HELIX platform, its collaboration opportunities, and its upcoming funding call, presented by HELIX Project Manager Anabela Veiga.

The “Hackathon Stories” session gave the floor to innovators who took part in the BIO-RED inter-regional hackathons. Rui Carvalho Santos from Portugal, Saulius Fomenko from Lithuania, and Krasimira Rusinova-Ilieva from Bulgaria shared how they found new teammates, tested their solutions in new ecosystems, and turned a local idea into a cross-regional story. The session was moderated by Kristina Eskenazi (HLSC, Bulgaria) and Simona Šimulytė (LithuaniaBio).

The event closed with the Solution Testing & Readiness Firetalk, an open conversation with international investors on what it takes to move a therapeutic, diagnostic, or advanced therapy from the lab to proof of concept: generating robust preclinical and clinical evidence, navigating regulatory pathways, and building the data package that convinces life-science investors to commit. The speakers were Christian Kumar of Med Tech Makers Lab (UK) and Dr. Georgios Varsos of VU Venture Partners (USA), and the session was moderated by Stamatiki Kritas of the Hellenic Biocluster (HBio).

The showcase reflected the idea behind the whole BIO-RED journey: hack locally, grow across Europe. You can find out more about the project and its Open Innovation Platform at bio-red.eu.

AccelBio took part in the Innovating Health Together Conference 2026 (IHTC’26), “Resilient and Sustainable Health Systems for the Future”, a two-day event held on October 27th and 28th, 2026, in Lisbon at Iscte – Instituto Universitário de Lisboa. Our Senior Translational Researcher, João Travassos Leandro, and our CSO, Sílvia Almeida, represented the team at the conference.

The conference focused on how health systems can remain resilient, sustainable, and responsive in the face of demographic, technological, economic, and environmental pressures. It brought together policymakers, health leaders, industry, startups, researchers, and investors to discuss topics such as resilient health systems and policy, sustainable models of care, data, digital and AI, personalised health and prevention, and global collaboration.

Building resilient health systems also means turning scientific discoveries into tomorrow’s therapies. At AccelBio, we work to bridge biomedical research and drug discovery, accelerating innovation through collaboration, and events like this one are a valuable opportunity to connect, exchange perspectives, and explore ways to bring science closer to patients.

On October 26th, 2026, the BIO-RED Inter-Regional Final Pitch Session brought together the 14 regional finalists from across all the BIO-RED Cross-Regional Hackathons, who presented their business cases to an international jury with members from the seven BIO-RED regions. Ten of them have now been selected for the BIO-RED Biotech & Pharma Accelerator Programme.

We are particularly proud that one of the selected teams, OrganoSynch, includes our PhD student Mafalda Vicente, who took part in the hackathon in Ioannina, Greece, alongside colleagues from across Europe. Congratulations to Mafalda and to the whole team!

The ten selected business cases are TwinOrg, CMC Master, RegBridge, Municipal Health Data & AI Gateway, RESP O₂, ScaleEU, OrganoSynch, RareBridge, ATMP Bridge™, and Transla EU. Congratulations to all of them, and thank you to every team that presented at the final pitch session.

The programme will be delivered in two parts. The first focuses on business case development, with three online workshops on value proposition and team, commercial strategy and market access, and regulatory pathway and IP strategy, held between November 17th and December 2nd. Each team will also benefit from 15 hours of personalised mentoring from a lead mentor and specialised experts. The second part prepares teams for fundraising and investment readiness, through two additional workshops, two online sessions, and a Final Showcase Event in Portugal in the second half of 2027. Overall, the programme represents €9,000 worth of support per business case, helping teams strengthen their business cases, prepare to raise public and private funding from mid-2027 onwards, and connect with relevant experts, partners, and investors across the BIO-RED ecosystem.

As a BIO-RED partner, AccelBio helped organise the Portuguese hackathon at Biocant Park in September and took part in the Greek hackathon in October, so it is a pleasure to see the project’s hackathons lead to concrete next steps for so many teams.

On October 15th and 16th, 2026, the Hellenic Biocluster (HBio) hosted the BIO-RED Cross-Regional Hackathon “Organoids & Drug Discovery: From Lab Models to Patient Decisions” in Ioannina, Greece. Run in a hybrid format, it was HBio’s very first hackathon, and AccelBio took part online with two members of our team.

Interregional teams from Greece, Bulgaria, Romania, Portugal, the Netherlands, France, and the USA worked together over two days to develop solutions to three challenges facing the sector today: standardising organoid models so that systems are reproducible and comparable across labs, smart organoid manufacturing and analytics to scale production and turn data into reliable insight, and precision medicine, bringing patient-derived models closer to clinical decisions. The hackathon also brought together local research, industry, and innovation stakeholders, who shared breakthroughs and good practices and offered insights on entrepreneurship.

We are proud of our team’s contribution. Our PhD student Mafalda Vicente joined one of the interregional teams, participating online alongside colleagues from across Europe, and her team secured 2nd place. Congratulations, Mafalda! Our Innovation Manager, João Maia, also attended online and was one of the jury members, bringing his expertise in innovation and entrepreneurship.

The competition continues: the winning teams from all the Cross-Regional Hackathons will compete in the BIO-RED Inter-Regional Final Pitch Session on October 26th for a place in the BIO-RED Biotech & Pharma Accelerator Programme. Good luck to all the finalists!

Our thanks go to HBio for hosting the event, and to all the participants, speakers, mentors, and jury members who made it so memorable.

TransBioNet, a new initiative funded by the European Union’s Horizon Europe programme, has been launched to help promising biomedical research across Europe progress towards investment readiness. The nearly €2 million project brings together seven partners from six countries to establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation.  

Through shared assessment tools, training, cross-border collaboration, and two Open Calls, TransBioNet will support early-stage drug discovery projects. Furthermore, the project will address fragmented access to specialised expertise and research facilities. These measures are needed because Europe has a world-class biomedical research base, yet too many promising drug discovery initiatives struggle to progress towards becoming investable projects, further development and market uptake. The challenge is not a lack of scientific excellence, but a fragmented translational ecosystem in which valorisation practices remain dispersed, academia-industry-investor hubs often lack critical mass, and access to specialised support is uneven across countries and regions.

In drug discovery, this gap is particularly difficult to overcome. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), bringing a new medicine to market takes on average more than 10 years, with research and development costs often exceeding €3 billion and success rates as low as just one to two compounds for every 10,000 tested. Amid growing competition, Europe’s share of global commercial drug trials fell by 10 percentage points between 2013 and 2023. 

Coordinated by Associação AccelBio in Portugal, TransBioNet will address this translation gap between laboratory discoveries and marketable therapies by building a European network of knowledge valorisation intermediaries: Technology Transfer Offices (TTOs), clusters, incubators, accelerators and innovation managers. These organisations and professionals connect academic research with SMEs, industry and investors, and help to evaluate intellectual property, assess early-stage assets, navigate regulatory requirements and identify funding opportunities.

"Promising drug discovery projects should not be limited by where they are based or by how easily they can reach the right people, facilities and partners," said Bárbara Gomes, CEO of Associação AccelBio and TransBioNet Project Coordinator. "With TransBioNet, we want to make cross-border collaboration more practical for early biomedical innovation, so that strong ideas can be assessed, de-risked and connected with the guidance they need to reach the next stage of development." 

To translate this network into practical support, TransBioNet will develop shared digital tools, training resources, and policy recommendations. Two consortium partners, Danish Life Science Cluster and Health & Life Sciences Cluster Bulgaria, will jointly lead ecosystem mapping and stakeholder consultations. Their findings will feed into the TransBioNet Charter, drafted and validated by InnoStars with contributions from all partners. The Charter will set out shared principles and policy recommendations for supporting early-stage drug discovery across Europe, while strengthening alignment with European and national innovation strategies and the objectives of the EU Biotech Act. 

The TransBioNet Digital Platform will serve as a one-stop hub for learning, matchmaking and project assessment. EATRIS ERIC will lead its development, drawing on its European network of translational research institutions. Associação AccelBio will lead the development of the Valorisation Assessment Toolkit to support more standardised evaluations of early-stage projects, while Biocant Park will coordinate the European Infrastructure Atlas, mapping research infrastructures and services relevant to biomedical translation across Europe. 

Alongside these tools, the Digital Training Academy and Community of Practice will strengthen peer learning, mobility and collaboration among intermediaries. Associação AccelBio will lead the Academy’s development, while LithuaniaBio will coordinate cross-border secondments to support skills and knowledge exchange between European ecosystems. 

"Navigating the complex landscape of biomedical translation requires better access to scientific expertise, advanced facilities, regulatory guidance and practical assessment tools," said Cansu Tekin, Innovation Manager, EATRIS ERIC, leading the development of TransBioNet’s Digital Platform. "By integrating the Valorisation Assessment Toolkit and the European Infrastructure Atlas into a single digital environment, TransBioNet will give intermediaries and early-stage innovators a clearer set of tools to help evaluate, de-risk and progress drug discovery assets more efficiently." 

Beyond building shared tools and training resources, TransBioNet will test its approach through two Open Calls for early-stage drug discovery projects, targeting research organisations, academic teams, SMEs and start-ups with validated targets or identified compounds. The scheme will select 12 projects for a 12-month acceleration programme featuring tailored mentoring, bootcamps, access to mapped infrastructures and services, and visibility through the TransBioNet platform. The three highest-ranked projects in each call are also planned to receive direct financial support for validation experiments. 

"Building shared tools is only part of the task. TransBioNet is also designed to engage the wider biomedical innovation ecosystem and create tangible results beyond the consortium," said Szilárd Szobol, Managing Director of InnoStars, which leads the TransBioNet project’s work on Open Calls, communication and dissemination activities. "Through the Open Calls, we will support promising early-stage drug-discovery projects coming from European start-ups or academia to accelerate their biomedical discoveries into clinical and societal impact." 

Regional inclusivity is built into this model. The selected Open Call projects are intended to include teams from Widening countries and under-represented regions, giving these teams access to expertise, services and specialised facilities beyond their local ecosystems. 

The TransBioNet consortium brings together seven organisations from six countries, combining expertise in biomedical valorisation, drug discovery, research infrastructures, innovation support, training and technology transfer. Coordinated by Associação Accelbio in Portugal, it includes Biocant Park, also based in Portugal; EATRIS ERIC in the Netherlands; EIT Health InnoStars e.V. in Germany; Danish Life Science Cluster in Denmark; Health & Life Sciences Cluster Bulgaria; and LithuaniaBio in Lithuania. 

 

About TransBioNet 

TransBioNet (Accelerating Biomedical Translation through a European Network of Knowledge Valorisation Intermediaries) is a 36-month Horizon Europe Coordination and Support Action coordinated by Associação Accelbio in Portugal. Bringing together seven partners from six countries, it supports early-stage drug discovery by strengthening cooperation between research, innovation support organisations, industry and investors. 

 

EU Funding Acknowledgement 

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101291691. 

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or  European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.”

From October 12th to 14th, 2026, the AccelBio team stepped away from the lab and the office for a three-day leadership workshop delivered by chaperone, led by Ana Isabel Azevedo.

Over the three days, the team explored what it truly means to lead: starting with self-leadership, moving on to leading others, and concluding with leadership in action. The progression gave everyone the space to reflect, challenge themselves, and grow, both individually and as a team, and the overall experience left a lasting impression on all of us.

Building a strong team goes beyond scientific excellence. Developing leadership skills, strengthening communication, and reflecting on how we work together are just as important in driving AccelBio’s mission forward.

We would like to thank Ana for leading such an engaging and inspiring workshop!

AccelBio’s CEO, Bárbara Gomes, attended the workshop “Knowledge Valorisation in Action: from Results to Policy” on October 8th, 2026, at the Centre Albert Borschette in Brussels. The event was organised by the European Research Executive Agency (REA), in cooperation with the European Commission’s Directorate-General for Research and Innovation, and brought together a cluster of Horizon Europe projects that piloted new approaches to knowledge valorisation.

The day opened with remarks from Martin Špolc, Director for Prosperity at DG Research and Innovation, and Stephen Collins, Director of REA. It continued with testimonials from project partners on how valorisation methodologies changed their business plans, partnerships, and relationships with citizens, before moving on to sessions on bringing research results to society and bringing research results to the market. Speakers presented lessons from projects such as CO-VALUE, BEAGLE, KALEIDOS, and VOICE, covering topics from citizen engagement and living labs to industry-academia collaboration and user-driven innovation in healthcare. The afternoon was dedicated to a plenary discussion on carrying these learnings forward, followed by a wrap-up from Iphigenia Pottaki of DG Research and Innovation.

Knowledge valorisation is at the heart of AccelBio’s work. As a collaborative laboratory bridging academia and industry, we are committed to translating scientific discoveries into real-world impact, and we coordinate TransBioNet, a European project building the first pan-European network of knowledge valorisation intermediaries dedicated to drug discovery. Events like this are a valuable opportunity to learn from other projects, connect with the wider European valorisation community, and keep our work aligned with the policy conversation

From September 30th to October 2nd, 2026, the neuromuscular disease research community gathered aboard the SS Rotterdam for the iPSC Modeling in Neuromuscular Disorders Meeting (iMND meeting 2026), three days of sharing and discussing the latest advances in the field. Our Principal Scientist in Advanced In Vitro Systems, Afonso Malheiro, took part in the meeting and was one of the selected speakers.

Scientists from around the world presented innovative strategies to model neuromuscular disorders, with a particular focus on the use of induced pluripotent stem cells (iPSCs) to study diseases such as amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) and spinal muscular atrophy (SMA).

On the first day, September 30th, Afonso spoke in the afternoon session “Therapeutics and Toxicology”, where he presented AccelBio’s latest advances in developing a human-based platform for modelling sporadic ALS, with the ultimate goal of enabling drug screening and accelerating the discovery of new therapeutic strategies.

The meeting was a great opportunity to exchange ideas, connect with fellow researchers, and contribute to the ongoing efforts to advance neuromuscular disease research. We are already looking forward to the next meeting, in Aachen in 2028.

Our COO, Ricardo Viais, represented AccelBio at BioSpain 2026, the international biotech trade show and partnering event held in Bilbao, Spain, from September 29th to October 1st, 2026, under the theme “Bioinnovation that clicks”.

The event brought together biotech companies, investors, and ecosystem players from Spain and beyond, offering a valuable setting to meet potential partners, explore new collaborations, and look ahead at opportunities for AccelBio.

It was also a chance to learn from Spain’s thriving regional biotech ecosystems. Ricardo attended the panel on “The role of regional ecosystems in driving the biotech sector”, a topic that closely reflects AccelBio’s own mission of strengthening the Portuguese biotech ecosystem and connecting it to Europe.

Participating in international events like BioSpain is part of how AccelBio builds partnerships and brings new ideas and opportunities back to the national ecosystem.

On September 29th, 2026, Biocant Park in Cantanhede hosted the Portugal Centro Region BIO-RED Cross-Regional Hackathon, which AccelBio helped organise together with the other Portuguese BIO-RED partners: Biocant Park, INOVA+, and the Região Metropolitana de Coimbra (CIMRC). The event followed a warm-up evening on September 28th, with ice-breaker activities and bilateral matchmaking to welcome participants.

The hackathon builds directly on the ATMP Thematic Lab organised by AccelBio in June, which identified three systemic gaps in the development of advanced therapy medicinal products (ATMPs). Participants were challenged to develop viable, scalable, interregional business models for each of them: making ATMP regulatory expertise accessible, affordable, and reusable for biotech companies; bridging the talent gap between the research laboratory and GMP manufacturing; and making GMP manufacturing capacity more visible and accessible across the ecosystem.

The day began with a welcome from Ana Moreira and Joana Branco of Biocant Park. Our Innovation Manager, João Maia, then presented the challenges generated in the Thematic Lab, followed by a business case briefing by Jorge Figueira from the University of Coimbra. Throughout the day, interregional and multidisciplinary teams, with participants from Portugal, France, Greece, and Lithuania, worked to define their challenge and value proposition, assess viability, market potential, and funding routes, and build a roadmap. In the afternoon, the teams presented their pitches to an international jury, which evaluated them on innovation, technical feasibility, commercial viability, alignment with BIO-RED, interregional added value, and team engagement.

The winning teams will now compete in the Inter-Regional Final Pitch Session on October 26th, 2026, for a place in the BIO-RED Biotech & Pharma Accelerator Programme. We look forward to attending and wish all the teams the best of luck.

Our thanks go to Biocant Park for hosting such a successful and welcoming event, and to all the participants, speakers, experts, and jury members who contributed their knowledge, experience, and perspectives.

AccelBio’s CEO, Bárbara Gomes, attended the first day of the I Congresso Internacional de Investigação em Saúde Militar, held on September 25th and 26th, 2026, at the Fundação Champalimaud in Lisbon, where she presented the poster “Dual-Use Translational Science for Military Health.”

The congress brought together military health leaders, researchers, and emergency and disaster-response specialists from Portugal and abroad. Its programme was organised around three areas: military health in new conflicts, force protection and operational readiness, and research and innovation in military health. The first day included sessions on adapting emergency medical services during prolonged crises, applied defence research in the NATO ecosystem, the use of artificial intelligence in military health, operational health and force protection, and the role of health systems in disaster response.

The AccelBio poster showed how the translational drug-discovery platforms already validated in academic and industry partnerships can be applied to the needs of armed forces. It outlined three dual-use pillars: physiological monitoring and operational readiness through multiomics-based biomarker panels, accelerated development of defence-adapted therapeutics such as antivirals, antibodies and vaccines through AI/ML-driven virtual screening, and personalised medicine for the military using organoids derived from a combatant’s own cells. It also set out how AccelBio can work with defence and health partners through co-development and risk-sharing projects and access to its core facilities.

Taking part in events across the wider health and innovation landscape is part of how AccelBio stays connected with developments beyond its core biotech and pharma ecosystem, and with the people working on them.

On September 24th and 25th, 2026, our researchers Mariana Branco and Inês Saraiva attended the 3rd Consortium Meeting of the IMPACT project, hosted by Maastricht University in the Netherlands. IMPACT ACM Project (Cardiogenomics meets Artificial Intelligence: a step forward in Arrhythmogenic Cardiomyopathy diagnosis and treatment ) is a European-funded initiative in which AccelBio is a partner, and the meeting brought the consortium together for two days of scientific exchange and planning as the project enters its final year.

Arrhythmogenic cardiomyopathy (ACM) is a genetic cardiovascular disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death, particularly among young people and athletes. The disease is characterised by the progressive loss of cardiomyocytes and their replacement by fibrotic and fatty tissue, leading to structural and functional abnormalities of the heart. There are currently no effective treatments able to prevent or reverse its progression, so clinical management focuses on reducing the risk of sudden cardiac death and slowing the disease.

IMPACT aims to advance the understanding of ACM by combining large-scale omics data from patients with structural and functional analyses of in vitro and in vivo disease models. By integrating these complementary sources of information, the project seeks to identify and validate new molecular mechanisms and therapeutic targets for ACM, paving the way for new therapeutic strategies. Within the consortium, AccelBio contributes with a human heart organoid platform that supports the characterisation of the structural and molecular pathological features of ACM. By modelling disease-associated phenotypes in human heart organoids, we aim to shed light on the mechanisms underlying disease progression and contribute to the identification and validation of potential therapeutic targets.

At the meeting, Mariana presented AccelBio’s latest results and contributions to the project. The scientific sessions covered clinical data, predictive genetics, advanced disease models, therapeutic screening, and bioimage analysis, with particular attention to how AI tools can support more efficient and standardised image analysis. Partners also discussed the main priorities, open challenges, and activities for the final year, as well as the next steps towards turning these findings into new opportunities for ACM research and therapy.

We thank Maastricht University for hosting the meeting, and all IMPACT partners for the contributions, discussions, and energy brought to these two days.

On September 24th, 2026, AccelBio’s Chief Scientific Officer, Sílvia Almeida, took part in the Innovative Health Initiative (IHI) Portuguese Health Innovation Ecosystem Stakeholders Meeting, organised by AICIB – Agência de Investigação Clínica e Inovação Biomédica at the Parque de Saúde de Lisboa. The meeting brought together national stakeholders and representatives of IHI to discuss Portugal’s participation in one of Europe’s main public-private partnerships for health research and innovation.

The afternoon opened with welcome remarks from Anabela Isidro, from the AICIB Board, and Ana Rita Pinto, the Portuguese IHI Delegate at AICIB. Niklas Blomberg, Executive Director of the Innovative Health Initiative, then presented IHI’s mission and project portfolio, followed by presentations from national stakeholders. After a coffee break, Ana Rita Pinto gave an overview of Portugal’s performance in IHI, setting the stage for the closing open discussion, “IHI in the spotlight: Challenges and Opportunities for Portugal”, moderated by IHI and AICIB.

The small-group format made for a candid and constructive exchange. Participants shared openly the main concerns and difficulties that Portuguese organisations face when applying to and taking part in IHI projects, and these were well received by the IHI team. The discussion also looked at how Portugal is positioned in IHI calls, including the challenges of engaging companies and the specific characteristics of the national biotechnology and pharmaceutical ecosystem.

For AccelBio, the meeting was a valuable opportunity to contribute the perspective of a collaborative laboratory that works every day at the interface between academia and industry. Strengthening Portugal’s participation in European initiatives such as IHI is closely aligned with AccelBio’s mission to connect the national ecosystem to international networks and funding opportunities, and we look forward to continuing this dialogue with AICIB, IHI, and our partners.

AccelBio took part in Biomeet 2026, the annual meeting of the Portuguese biotechnology sector organised by P-BIO – Associação Portuguesa de Bioindústria. The event took place on September 23rd and 24th, 2026, at the Taguspark Conference Centre in Oeiras, and the team attended as an Ecosystem Agent.

AccelBio also contributed to the programme agenda on the meeting's first day. During the morning coffee break, our Project Manager Marta Narciso presented the BioTransfer Maturity Assessment Concept on behalf of the BioTransfer team. In the afternoon, our CEO, Bárbara Gomes, moderated the roundtable “Bridging Science and Industry in Biotechnology”. Later in the day, during the afternoon Flash Presentations, our researcher Cláudia Miranda showcased OrganTech, a platform using hiPSC-derived organoids to accelerate preclinical studies and help reduce Phase 1 clinical trial risks.

Over the two days, the team had the opportunity to engage with researchers, entrepreneurs, and industry partners on topics at the core of AccelBio’s work: translating science into real-world impact. Biomeet is a key event for knowledge exchange, strategic partnerships, and the advancement of the biotech ecosystem in Portugal, and we are grateful to P-BIO for organising it and to everyone who visited our stand, attended our sessions, or took the time to connect with the team.

On September 1st 2026, TransBioNet officially began, a new European project coordinated by CoLab AccelBio aimed at accelerating the valorisation of European drug discovery research. The project held its online kick-off meeting on September 14th, bringing together the full consortium for a first working session on the project's goals, structure, and next steps.

TransBioNet establishes the first pan-European network of knowledge valorisation intermediaries dedicated to drug discovery, bridging the gap between academic research and clinical application to strengthen Europe's biomedical competitiveness. The project is built around five specific objectives: aligning policy through a shared TransBioNet Charter, developing modular valorisation toolkits, mapping Europe's research infrastructure, launching a digital platform to connect stakeholders, and establishing a training community to build skills across the network. These objectives are supported by a set of strategic pillars spanning policy reshaping, infrastructure connection, community and skills growth, sustainability, science advancement, and the tools needed to put valorisation into practice.

Among its key deliverables, TransBioNet will develop a dedicated Digital Platform, a Valorisation Assessment Toolkit, a European Infrastructure Atlas, and a Digital Training Academy, resources designed to serve a wide range of stakeholders across the drug discovery ecosystem, including academia, SMEs, industry and pharma, technology transfer intermediaries, policymakers, and ultimately society and patients.

The consortium brings together partners including CoLAB AccelBio, Health & Life Sciences Cluster (Bulgaria), Danish Life Science Cluster (Denmark), EATRIS (Netherlands), EIT Health Innostars (Germany), Biocant Park (Portugal) and LithuaniaBio (Lithuania). As project coordinator, AccelBio leads the overall project management and coordination (WP1) as well as the work package on capacity building, mobility, and community development (WP4). DLSC leads the work on policy alignment for biomedical valorisation (WP2), EATRIS leads the development of the knowledge valorisation toolkit and digital platform (WP3), and EIT Health Innostars leads both the launch of Open Calls and the project's financial support scheme (WP5) and the communication, dissemination, and exploitation activities (WP6).

The kick-off meeting gave partners the opportunity to align on the project's challenges and objectives, review the flagship results expected from each work package, and discuss the governance, reporting, and management tools that will guide the consortium's work over the coming years. The session also included statements from the Project Officer and the European Health and Digital Executive Agency (HaDEA), underscoring the European Commission's engagement with the project from its earliest stage.

With the consortium now aligned and its work packages underway, TransBioNet marks an important step in AccelBio's growing role in shaping European drug discovery valorisation, and CoLab AccelBio looks forward to leading this collaborative effort over the course of the project.

On June 16th, 2026, CoLAB AccelBio organized a Thematic Lab under the BIO-RED project, dedicated to "ATMP Development: Cell & Gene Therapy to GMP." The session brought together 45 participants including researchers, industry experts, and innovation stakeholders to discuss the challenges of translating cell and gene therapies from early-stage development to GMP-compliant manufacturing.

The Thematic Lab followed a structured, three-phase format designed to move from context-setting to concrete problem framing. Phase I, "Setting the Ground," opened with an overview and results of the BIO-RED project, followed by a problem-framing session led by Pascale Berthet, from CELL'ECTIV Consulting. Phase II, "Topics Discussion," featured a Q&A kick-off led by Lino Ferreira, from CIBB-UC, encouraging open exchange among participants on the technical and regulatory hurdles of advanced therapy medicinal products (ATMPs). In Phase III, participants voted on the challenges they considered most pressing, before the session concluded with a wrap-up and a look ahead to the next step: a Hackathon focused on turning the discussion's insights into actionable solutions. An optional matchmaking session followed, giving participants the chance to connect one-on-one and explore potential collaborations.

BIO-RED is a project funded by the European Union, and this Thematic Lab reflects CoLAB AccelBio's continued commitment to fostering dialogue between academia and industry on the practical challenges of bringing cell and gene therapies to patients. Building on the challenges identified during the session, the next step will be a Hackathon, to be held at Biocant Park, in Cantanhede, on September 29th, 2026, where participants will work hands-on to turn these insights into actionable solutions for ATMP development.

CoLab AccelBio held its annual Connecting Day on May 29th, 2026, at the Pavilhão de Portugal in Lisbon, bringing together researchers, innovators, policymakers, and partners from academia and industry for a day dedicated to translational research and collaboration in the life sciences.

The programme opened with an overview of CoLab AccelBio's growth, capacities, and assets by AccelBio's Management Team (Bárbara Gomes - CEO, Ricardo Viais - COO, Sílvia Almeida - CSO), followed by a keynote presentation on Translational Research by Bruno Dombrecht, Head of VIB Discovery Sciences. The day also featured two round table discussions: one exploring the challenges and opportunities of translational research in academia, and another examining the future of organoids in drug discovery.

Speakers included Bruno Dombrecht (VIB Discovery Sciences), Raúl Saraiva (3xP), João Leandro and Vânia Cardoso (CoLAB AccelBio); Aline Fernandes (OrganoStemTech), Raquel Cunha (CoLab TRIALS), Cláudia Miranda and Mariana Branco (CoLAB AccelBio).

The event also welcomed three members of CoLAB AccelBio's International Advisory Board — Ivo Lorenz, Katie Ellias, and Molly Harper — who travelled from the United States to Lisbon to share their perspective and guidance with the community.

The quality of the conversations throughout the day underscored the importance of building strong partnerships between academia and industry to drive meaningful progress in the life sciences. Beyond the discussions themselves, Connecting Day continues to serve as a space for partnering among academic, non-academic, and industry players. CoLab AccelBio's goal for the event is not only to foster genuine dialogue, but also to reinforce existing partnerships and establish new ones that help grow the Portuguese biotech ecosystem.

CoLab AccelBio would like to thank all speakers, its International Advisory Board members, the whole AccelBio team, and everyone who attended and helped make the day memorable. The organization looks forward to continuing these collaborations in the years ahead.

CoLab AccelBio was featured in the April 2026 issue (No. 196) of Portugalglobal, the magazine published by AICEP – Portugal's Trade & Investment Agency, in an article on Health and Life Sciences titled "A bridge between research and industry to create new drugs."

The article traces CoLab AccelBio's journey since its founding in 2021: a non-profit association bringing together academic institutions, biotech companies, an investment fund and a technology park, positioned as an intermediary in the early stages of new drug development. Its work focuses on the pre-clinical phase, from target validation through to clinical-trial readiness, aiming to increase the number and quality of drug candidates with therapeutic and market potential.

As Ricardo Viais, Chief Operations Officer of CoLab AccelBio, notes in the piece: "Our mission is to accelerate the pre-clinical phases of drug discovery, translating scientific discoveries into assets with clinical and investment potential."

Over three years, CoLab AccelBio has supported 14 projects spanning neurological disease, immunity, infection, gastric cancer and obesity, raising more than €2 million in competitive funding in addition to core funding under the Missão Interface programme. The team now numbers 20 people, mostly PhD holders.

The article also highlights a strong 2025 — with growth in services to national and international partners and six new projects approved — as well as the two technology platforms underpinning CoLab AccelBio's work: a medicinal chemistry platform using computation and AI, and an organoid platform based on lab-grown organ models for pre-clinical testing, reducing reliance on animal models.

Internationally, the piece points to CoLab AccelBio's involvement in European networks and initiatives such as the EU-funded BIO-RED project, as well as its role in bringing BioEurope Spring 2026 to Lisbon, reinforcing Portugal's international visibility in biotechnology.

Looking ahead to 2026, Ricardo Viais anticipates accelerating ongoing projects, launching a new Open Call, expanding services, and strengthening national and international partnerships.

Read the full article (PT) in the April 2026 issue (No. 196) of Portugalglobal, available here.

P-BIO, AccelBio, and Biocant Park are the Host Committee of BIO-Europe Spring 2026, one of Europe’s leading biotechnology partnering events, taking place in Lisbon, 23–25 March.

Portugal has always been defined by its spirit of connection and collaboration. Throughout our history, we have built bridges between continents, cultures, and communities. That same legacy inspires our biotechnology ecosystem today – where researchers, companies, and institutions work together to transform scientific discovery into real world solutions.

In this spirit, the Host Committee is coordinating a Portugal National Booth, designed to boost international visibility for the Portuguese ecosystem, foster partnerships and investment, and accelerate the journey from research to market. This national initiative brings together the country’s most innovative companies, research centers, and regional authorities in a unified platform to showcase Portugal’s strengths in biotechnology and life sciences.

BIO-Europe Spring attracts around 4,000 attendees, representing 1,500+ companies from 50+ countries, including 3,700+ leaders and innovators in a partnering environment that enables thousands of meetings between clients, companies, and investors, providing for an excellent opportunity for funding or international expansion.

The Portugal Booth is supported by the following organizations:
Beat Therapeutics; Bial; Bluepharma; Braga City Council; Cantanhede City Council; Lisbon City Council; Oeiras City Council; CoLAB Trials; LxBio; Rodon Biologics; Stemmatters; TargTex; Valvian; and Vector B2B.

This diverse group of supporters represents the collaborative nature of Portugal’s biotech ecosystem – spanning pharmaceutical companies, biotechnology startups, research institutions, and regional governments all united by a common goal: positioning Portugal as a hub for innovation and partnership.

We invite companies and organizations interested in exploring opportunities at the event to connect with us. Whether you’re looking for partnership opportunities or investment possibilities, we welcome the chance to discuss how we can work together to achieve shared goals.

 

CoLAB AccelBio joined BIO-RED partners in Paris for an in-person meeting hosted by Medicen Paris Region (12–13 January). 

Over two days, partners advanced discussions around: 

  • A strategic interregional roadmap and ecosystem-building initiatives in red biotech 
  • Staff exchanges, thematic labs, and policy roundtables 
  • The launch of a Biotech and Pharma Accelerator Programme to strengthen business cases and foster investment in emerging biotech solutions across regions 

We thank Medicen Paris Region for hosting and all partners for the productive exchanges supporting sustainable and impactful biotech innovation across Europe. 

AccelBio was represented at BIO-Europe in Vienna by Ricardo Viais and Bárbara Gomes. 

Following a productive event, Portugal’s life sciences presence continues to grow—through broader participation, stronger pipelines, improved infrastructure, and an increasingly collaborative approach to delivery. We also highlight the excellent Portugal booth delivered by AICEP Portugal Global at this autumn edition. 

We are honoured that BIO-Europe Spring 2026 will be hosted in Lisbon, with AccelBio, Biocant Park and P-BIO serving as the Host Committee. We look forward to welcoming partners, showcasing capabilities, and accelerating impactful collaborations. 

The IMPACT EU consortium gathered in Milan on 9–10 October 2025 for its 2nd Year Meeting, hosted by Consorzio Italbiotec. 

Partners shared results, reviewed progress, and aligned on upcoming activities focused on arrhythmogenic cardiomyopathy (ACM). Bárbara Gomes presented AccelBio and our role in supporting biomedical innovation, while Mariana de Araújo Branco showcased how the organoids under development will contribute to identifying new therapeutic targets and therapies for ACM. 

We are proud to be part of this journey toward more precise and effective therapies for cardiovascular disease. 

AccelBio is proud to share the approval of two projects under the FCT Exploratory Projects call: 

  1. Deciphering MicroRNA Mechanisms of Action via High-Dimensional Multiparametric Cell Painting Assay
    A cutting-edge Cell Painting approach to map miRNA mechanisms by matching phenotypic signatures to profiles generated with FDA-approved compounds. 
  1. Exploiting Novel Host-Directed Antimicrobials for Combating Infections by Staphylococcus aureus
    A newly established approach to identify host-directed candidates that may be used alone or in combination with classical antibiotics. 

These projects reinforce our commitment to enabling high-impact translational science and expanding innovative pipelines. 

Under COMPETE P2030, AccelBio has secured approval for Bio-Transfer: Biomedical Knowledge Commercialization Program, a joint initiative led by i3S, AccelBio, and CoLAB Trials. 

Bio-Transfer aims to strengthen biomedical technology transfer and commercialisation through an integrated national framework and five interconnected actions, including: 

  • A progress-tracking directory for innovation ready to transition to bioindustry (Bioinnovation Golden Basket) 
  • A learning and sharing cycle of talks (BioInnovators Podcast) 
  • A CRM system connecting target companies and expert connectors (Licensing Operating System) 
  • Maturation and industry-readiness activities (Bioinnovation Step-Ups) 
  • A partnership-promotion tour linking startups and industry (Bio Meetings Route) 

The programme will also track the progress of supported startups and consolidate learnings into a community-facing white paper. 

Cláudia Miranda and Mariana de Araújo Branco joined HiTech 2025 with AccelBio’s project OrganTech—a cutting-edge platform using hiPSC-derived organoids to accelerate preclinical studies and help reduce Phase 1 clinical trial risks. 

Through the programme, the team developed a dedicated business development plan to explore the market potential of AccelBio’s organoid platforms and reinforce how deep tech and biomedical innovation can address real industry needs. 

Interested in partnering around organoid-based models for efficacy and safety? Let’s talk. 

AccelBio participated in the national event “7 Years of CoLABs: Impact and Perspectives”, held at the Pavilhão do Conhecimento (Lisbon) and organized by FCoLAB. 

The event brought together 41 Collaborative Laboratories, alongside public and private organisations and key decision-makers, to reflect on the impact of the CoLAB model and discuss future priorities for a more innovative, sustainable, and competitive Portugal. It combined strategic debate moments with the CoLABs Showcase, where CoLAB AccelBio presented its work, capabilities, and vision—strengthening connections and sparking new collaborations. 

AccelBio’s ecosystem was also represented in the programme debates by Vera Moura (Basinnov), contributing to a multisectoral roundtable on socioeconomic impact, internationalisation, competitiveness, innovation, and sustainability. 

The CoLAB AccelBio Connecting Day, held at Biocant Park, brought together our associates, members of the International Advisory Board (IAB), and key partners from the biotech research and innovation ecosystem. 

This year, we expanded the format by inviting external entities beyond our associates—creating stronger interaction not only with AccelBio’s work, but also with our IAB experts. We believe this broadened perspectives, strengthened relationships, and opened new pathways for collaboration—an approach we intend to maintain and develop in future editions. 

A highlight of the day was a forward-looking discussion on US vs EU innovation ecosystems, including themes such as funding dynamics, regulatory pathways, speed of execution, industry engagement, and knowledge valorisation. 

Interested in joining future editions or engaging with our IAB? Contact us. 

CoLAB AccelBio is pleased to announce that we are officially a partner in BIO-RED, a European Commission-funded consortium. 

Together with a strong network of partners across Europe, BIO-RED will support academic labs and emerging pharma and biotech companies in the development and adoption of green technologies in red biotechnology—accelerating more sustainable innovation across the life sciences value chain. 

If your organisation is developing sustainable biotech solutions, we’d love to connect. 

https://www.linkedin.com/company/bio-red/posts/?feedView=all

AccelBio joined a Portuguese delegation in the EIT Health InnoStars Mission: Deep Dive into the UK Healthcare Innovation Ecosystem (28–29 April). 

The delegation included partners from Universidade Nova de Lisboa, University of Lisbon, University of Coimbra, ULS de Coimbra, and CoLAB AccelBio, alongside representatives from the Executive Board of NHS Portugal and AICIB. 

Organised by EIT Health InnoStars, supported by the British Embassy Lisbon, and hosted by King’s College London and the London Institute for Healthcare Engineering, the mission provided a high-value opportunity to explore the UK’s healthcare innovation landscape, connect with leading institutions, and identify collaboration pathways. 

Want to explore UK–Portugal collaboration opportunities? Reach out to AccelBio. 

Portugal has been announced as the Host Country for BIO-Europe Spring 2026, one of Europe’s leading partnering events in biotechnology and life sciences. 

The 19th edition, held in Milan (17–19 March), marked a milestone for the Portuguese life sciences ecosystem, culminating in the announcement that Lisbon will host BIO-Europe Spring 2026 (23–25 March 2026). The event typically attracts around 4,000 participants, representing 1,500+ companies from 50+ countries. 

This achievement reflects a joint national effort led by Biocant Park, CoLAB AccelBio, and P-BIO – Portuguese Bioindustry Association. 

Stay tuned for updates on Portugal’s Host Committee activities and how to engage with BIO-Europe Spring 2026 in Lisbon. 

CoLAB AccelBio has secured its first European-funded project by joining IMPACT through the Hop-On mechanism. 

IMPACT is an EIC Pathfinder initiative with an ambitious goal: to pave the way for novel therapies for major cardiovascular diseases, by implementing an AI-based integration of clinical and multi-omics data from patients with arrhythmogenic cardiomyopathy (ACM). 

ACM is a genetic condition associated with ventricular arrhythmias and sudden cardiac death, particularly in young people and athletes. As no effective disease-modifying treatments are currently available, IMPACT aims to strengthen the understanding of genotype–phenotype relationships by combining large-scale patient -omics with structural and functional data from in vitro and in vivo models. 

Interested in collaborating on ACM-focused translational research? Get in touch with our team. 

In a groundbreaking project funded by the La Caixa Foundation, AccelBio and Marc Veldhoen’s team, from GiMM, have joined forces to explore a novel strategy for selectively modulating T cell responses. Infectious and inflammatory diseases, whose global prevalence is on the rise, remain among the leading causes of mortality worldwide. Many of these conditions are linked to the activity of T cells, a type of white blood cell critical for coordinating immune responses against pathogens. However, T cells can sometimes become overactive, leading to severe conditions such as fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.

Current treatments often rely on broad-spectrum immunosuppressive drugs, which, while effective, come with significant side effects and an increased risk of infections. This highlights the urgent need for therapies that can selectively inhibit T cell activity without compromising the overall immune response.

Marc Veldhoen’s team has identified a key factor in T cell activation, which the research will investigate as a new therapeutic target. In collaboration with Silvia Almeida and Vânia Cardoso from CoLAB AccelBio, experts in drug discovery, the team will work to identify drug candidates that modulate T cell response while preserving the immune system’s protective functions. This project aims to develop tools to reduce the side effects commonly associated with current treatments for infectious and inflammatory diseases, potentially leading to safer and more effective therapies.

This innovative approach holds promise for advancing targeted therapies that improve patient outcomes in managing complex immune-related conditions.

CoLAB AccelBio, in collaboration with AICEP Portugal Global, Biocant Park, and supported by EIT Health, is excited to announce the upcoming EIT Morning Health Talks event on “How Open Innovation can Contribute to Healthcare Transformation.” This pivotal event, designed to foster connections and collaborations across the biomedical sector, will bring together leading voices from Portuguese R&D, industry innovators, and investors to explore how open innovation can advance healthcare solutions.

Why Attend? The event will provide a unique platform for interaction among Technology Transfer Offices, top-tier researchers, biotech and pharmaceutical professionals, and investors, encouraging collaborations that are vital for accelerating healthcare innovations. Attendees will gain valuable insights into the latest in biomedical R&D and transformative healthcare practices. An anticipated highlight of the event will be a keynote address by Dr. Pascale Redig from KU Leuven, offering international insights on innovative healthcare approaches and future trends.

Event Details

  • Date: November 28, 2024
  • Location: Biocant Park, Cantanhede, Portugal (both onsite and online participation options available)

Spaces are limited! Reserve your spot now to participate in this influential gathering.

You can view the full program and register here.

Join us to be part of this transformative discussion on open innovation in healthcare.

We were thrilled to attend the Encontro Ciência 2024, organized by the Foundation for Science and Technology (FCT), the University of Porto, and Ciência Viva, held from July 3 to 5 at Alfândega do Porto.

Science and Technology Exhibition: at our stand in the Science and Technology Exhibition, visitors had the opportunity to learn more about our cutting-edge drug discovery and development services. We were delighted to engage with many attendees and share insights into our innovative approaches.

 Themed Sessions Participation: we were honored to participate in two impactful themed sessions:

  • How Can CoLABs Support Global Health Challenges?
  • The Role of Biotechnology in Healthcare

These sessions allowed us to delve into critical discussions about the contributions of collaborative laboratories (CoLABs) to global health and the pivotal role biotechnology plays in advancing healthcare.

 Watch Our Interview: don't miss the interview with Bárbara Gomes, available on Encontro Ciência's YouTube channel.

 A thank you to everyone who visited our stand and participated in our sessions. Your engagement and interest in AccelBio's role within the Portuguese biotechnology ecosystem were truly inspiring.

#Ciencia2024pt #CoLABs #Health #Biotechnology

CoLAB AccelBio, driven by a commitment to advancing science, attended the BIO International Convention in San Diego. As the largest and most comprehensive event for biotechnology, the convention represents the full ecosystem of biotech with more than 18,500 industry leaders from across the globe. The event aimed to fulfill specific goals, including gathering feedback on R&D capabilities, exploring collaborations, and broadening perspectives through diverse interactions.

After the eligibility check of the proposals submitted to the CoLAB AccelBio - Open Call 2024, 22 proposals were evaluated by three reviewers each. The proposals then moved to the second phase: the interview. Based on the combined grades from both stages, the projects FATLOSS and COMASLINK were selected for support by CoLAB AccelBio. We would like to express our gratitude to all participants for their hard work and innovative ideas. Your contributions are highly valued, and we encourage you to continue pursuing your groundbreaking projects.
The table with the final scores of each eligible project is available here:

 

Ranking

Acronym

PL

Host Institution

Rate

Projects selected for interview

1

FATLOSS

Luisa Figueiredo

iMM

8.46

2

COMASLINK

Sandra Vaz

FMUL

7.67

3

EPI4CANCER

Marta Costa

ICVS

7.35

4

VIPandemic

Nuno Santos

iMM

7.27

5

RANKit

Sandra Casimiro

iMM

7.20

6

TargetCNM

Edgar Gomes

iMM

6.72

7

SIRT1

Maria Manuel

CNC

6.70

8

INVERT

Ana Sofia Ribeiro

i3S

6.50

9

Break

Sandra Pinto

IST

6.43

10

OsteoGold

Pedro Castro

iMM

6.40

11

ENDOMET

Cristina Nogueira

ICVS

5.83

12

HEMIPHOL

Nuno Santarém

i3S

5.63

13

DRUGMTB

Hugo Fraga

i3S

5.57

14

NANO4CURE

Sónia Abreu

iMM

5.55

15

GENESIS

Tiago Fernandes

IST

5.53

16

Refine

Raquel Almeida

i3S

5.48

17

ALZHEX

Gonçalo Garcia

FFUL

5.38

18

BIGT-FFI

Ana Rita Álvaro

CNC

5.34

19

Antibiomech

Ricardo Monteiro

i3S

5.17

20

HIMN

Ângela Sousa

UBI

5.17

21

PerOxy

Natércia Lopes

IST

4.22

22

G-Lycos

Vasco Bonifácio

IST

4.05

CoLAB AccelBio had the privilege of hosting its first International Advisory Board (IAB) Meeting on February 26th, at Instituto de Medicina Molecular. The gathering aimed to set the stage for our organization's future by discussing strategic priorities, defining objectives, and gathering insights from our advisory board members.

The meeting buzzed with engaging discussions as we delved into the heart of CoLAB AccelBio's mission. With our IAB members' invaluable input, we charted a course that aligns our goals with industry trends and best practices. Their diverse perspectives enriched our conversations and provided fresh insights into the evolving landscape of biotechnology.

Throughout the day, lively exchanges of ideas fueled our excitement for the future.We found ourselves so deeply engrossed in the discussions that the notion of capturing a photograph slipped our collective minds entirely. Despite the absence of a snapshot, the memories and outcomes of the meeting remain vivid. We left the meeting with a renewed sense of purpose and a clear direction for advancing CoLAB AccelBio's mission. With our IAB's guidance, we are confident in our ability to drive meaningful progress and innovation in the biotechnology and pharma sectors.

Please check further information about our IAB members here.

We are thrilled to announce the launch of the AccelBio Open Call, a competition aimed at accelerating biomedical innovation in Portugal. Our primary mission is to facilitate the successful transfer of scientific knowledge to the economy by fostering the development of products and businesses in drug discovery.

Objective: The AccelBio Open Call seeks to identify and support projects with the most promising prospects of transitioning from research into clinical product candidates. Our ultimate goal is to capitalize on the best Portuguese discoveries and transform them into innovative drug assets.

Focus Areas: We invite proposals from Portuguese public or non-profit legal entities, including universities, research centers, and hospitals. Eligible projects should have potential as pharmaceutical therapies, particularly in the following therapeutic areas:

  • Oncology
  • Neurosciences
  • Infectious diseases
  • Immunology
  • Metabolism
  • Cardiovascular

Support Offered: Selected projects will receive a financial award of up to 50,000€ to cover services and consumables. Additionally, we will provide assistance in preparing a comprehensive value creation plan. This plan, developed with the support of the AccelBio team, will have a duration of 18 months and will encompass a series of experiments necessary to drive a drug discovery project effectively to the pre-clinical candidate stage.

How to Apply: Interested parties are invited to submit proposals outlining their research activity and its potential to be developed into assets with clinical therapeutic potential.

Submission Deadline (Extended): The deadline for proposal submission is April 14th, 2024

Join Us in Transforming Scientific Ideas into Clinical Solutions: We believe that collaboration and innovation are key drivers of progress in biomedical research. By participating in the CoLAB AccelBio Open Call, you will have the opportunity to contribute to the advancement of healthcare and make a meaningful impact on patients' lives.

For more information and to submit your proposal, please check the Guidelines and the Application Template.

Let's accelerate biomedical innovation together!

AccelBio participated in BioEurope event in Munich from November 6th to 8th, actively advancing the frontiers of biotech. With a commitment to advancing the boundaries of biotech, AccelBio strategically utilized the event to explore synergies with industry leaders, investors, and potential partners.

At the conference, AccelBio unveiled its cutting-edge Organoids platform, presenting a pivotal opportunity to forge partnerships that will expedite the development and commercialization of groundbreaking medicines.

CoLAB AccelBio is one of the partners in the "Health from Portugal" Mobilizing Agenda, led by Prologica, and approved under the Portuguese Economic Recovery and Resilience Plan (recuperarportugal.gov.pt).

The main aim of the agenda is to position Portugal as a world reference hub in the design, development and production of advanced solutions for the health markets, based on innovation and technology. HfPT will focus on four areas: (i) the development of smart health solutions aimed at the digital medtech segment; (ii) the creation of a national smart health data repository of international reference; (iii) capacity building for the growth and sophistication of the clinical studies segment in the country; and (iv) the creation of solutions that valorise the potential of the ecosystem for collecting and benchmarking clinical data and costs associated with healthcare provision.

Starting date: 01/01/2023
Estimated completion date: 31/12/2025

Eliglible Investment (Agenda): 90,6 million €
Eliglible Investment (AccelBio): 708.779,76 €


O CoLAB AccelBio é um dos parceiros da Agenda Mobilizadora "Health from Portugal", liderada pela Prológica, e aprovada no âmbito do Plano de Recuperação e Resiliência (recuperarportugal.gov.pt).

A agenda HfPT visa posicionar Portugal como um hub de referência mundial na conceção, desenvolvimento e produção de soluções avançadas dirigidas aos mercados da saúde, assentes na inovação e tecnologia. A HfPT incidirá em 4 áreas de aposta: (i) desenvolvimento de soluções smart health dirigidas ao segmento do medtech digital; (ii) criação de um repositório inteligente nacional de dados de saúde de referência internacional; (iii) capacitação para o crescimento e sofisticação do segmento dos estudos clínicos no país; e (iv) criação de soluções que valorizem o potencial do ecossistema de recolha e benchmark de dados clínicos e custos associados à prestação de cuidados de saúde.

Data de inicio: 01/01/2023
Data (prevista) de conclusão: 31/12/2025

Investimento Elegível (Agenda): 90,6 million €
Investimento Elegível (AccelBio): 708.779,76 €

In partnership with the Portuguese Society of Stem Cells and Cell Therapy (SPCE-TC), and in an effort to promote and inspire research in the field of Regenerative Medicine, Crioestaminal launched the third edition of this prestigious award. The announcement and presentation of this honor took place during the ETRS and SPCE TC joint meeting, held at Universidade de Coimbra from October 11 to 13.

The prestigious award was granted to our very own Mariana Branco in recognition of her remarkable work titled, "Human Multilineage Pro-Epicardium/Foregut Organoids: Catalysts for the Development of an Epicardium/Myocardium Organoid."

Congratulations Mariana!

AccelBio, in collaboration with its Associate, Instituto de Medicina Molecular, had the distinct pleasure of hosting Anton Hutter from Venner Shipley for an insightful workshop on "Navigating Intellectual Property Challenges in Pharma and Biotech."

This dynamic training session was meticulously crafted to offer participants a deep and comprehensive understanding of the intricate landscape of intellectual property (IP) within the pharmaceutical and biotechnology sectors. The workshop was designed to empower professionals, researchers, and entrepreneurs with the knowledge and practical tools required to safeguard their innovations, adeptly traverse IP challenges, and optimize the value of their intellectual property assets.

The workshop reaffirmed AccelBio's commitment to fostering excellence in the fields of pharmaceuticals and biotechnology, ultimately supporting innovation and the protection of intellectual property.

We extend our sincere appreciation to all who joined us for this enlightening session. Keep an eye on our platforms for future opportunities to engage in such informative events and continue the journey toward advancing science and innovation.

 

AccelBio proudly took center stage at the European Researchers' Night 2023, captivating audiences with an exploration into the world of 3D organoids and their impact on the discovery and development of new medicines.

With an unwavering commitment to scientific innovation, AccelBio's dedicated team embraced this opportunity to share their expertise and insights with an eager and curious audience. The event provided a unique platform for bridging the gap between science and the public, fostering a deeper understanding of the remarkable potential of 3D organoids in advancing healthcare.

We extend our gratitude to all those who attended and engaged with AccelBio during this event.

AccelBio, driven by a commitment to advancing science, attended the BIO International Convention in Boston. The event aimed to fulfill specific goals, including gathering feedback on R&D capabilities, exploring collaborations, and broadening perspectives through diverse interactions. The AccelBio team met with Scientific Advisory Board members and engaged with the Portuguese Biomedical community. Entrepreneurship and innovation were at the heart of their mission.
During the event, they connected with various stakeholders, from companies to research organizations. Evenings at the BIO Convention offered a platform for fostering global collaboration.

AccelBio's participation exemplifies our dedication to scientific excellence and our pursuit of a healthier future.

Industry-academic partnerships are becoming more popular as pharmaceutical and biotech companies seek to harness the innovation and human capital within research institutions. Most companies engage in academic collaborations in order to expand their programs in the discovery of new targets, molecules or disease models. But how can we promote and manage such collaborations?

On May 12th, AccelBio will host a workshop together with a round table to discuss how academia and pharmaceutical and biotech industries can collaborate to promote technological advancement and innovation.

Interested?

Please register here.

 

Speakers for the event: 

Joachim Vogt

Joachim Vogt is Director Search & Evaluation International at AbbVie. He is responsible for the identification of European business opportunities across all indications and technologies of interest for AbbVie and serves as key contact for European partners, including academic institutions, biotech companies, venture capital, governments and non-profit organizations.

 

 

João Seixas

João Seixas is the CEO of TargTex, a Portuguese biotech company developing an innovative treatment to the most common and aggressive type of primary brain tumour - Glioblastoma. TargTex is a spin-off from Instituto de Medicina Molecular.

 

 

Rui Brito

Rui Brito is the CEO of BSIM Therapeutics is a biotech company focused on the design of organ-targeted, high-quality drug candidates for the treatment of transthyretin-mediated amyloidoses. BSIM is a spin-off from Coimbra University.

 

 

Nuno Prego Ramos

Nuno Prego Ramos is the CEO of CellmAbs, a fast-growing biotech company with an international, experienced team that has generated several preclinical candidates targeting solid tumors based on a world-leading understanding of cancer-specific glycan targets. CellmAbs is a spin-off from NOVA University of Lisbon.

 

Tobias Silva

Tobias Silva is Strategic Partnerships and Product Development Director at Bluepharma. Bluepharma Group is today one of the most entrepreneurial and innovative Portuguese group in the pharmaceutical sector. Bluepharma's activity goes through the entire value chain of the drug, from R&D to the market.

 

 

David Braga Malta

David Braga Malta is a Life Sciences Entrepreneur, Inventor and Investor. David is currently managing the Health PE fund of Group Pictet, an investment-led service company. As an entrepreneur David founded LiMM, Cell2B and BoostPharma

The launch of new drugs in the market has the solid purpose of fulfilling patient needs. Nowadays, the approval of new drug products depends on evidence of efficacy, safety and quality, reflected in regulatory requirements, which are rules of law to protect individuals.

The grounds for such requirements were only formally set in stone in 1962, under the Kefauver-Harris or Drug Efficacy Amendment, following the unfortunately well-known tragedy caused by the use of Thalidomide as a morning sickness treatment during pregnancy. This amendment made it mandatory not only to prove the safety of drugs, but also to provide evidence on the effectiveness based on adequate and well controlled clinical studies. It also established requirements for compliance with Good Manufacturing Practices and the filling of an adverse events report.

While moving the drug advertisement under the umbrella of the FDA, all the information would be filed for approval and afterwards breaking through the market. The previously 1938 approved Federal Food, Drug and Cosmetic Safety Act already engaged pharma companies in animal toxicology to support the entry of new drugs into the market.

Moreover, as of 1981, the conformity to follow formal standards for the protection of humans (and strengthen of Institutional Review Boards, IRB) has become more stringent (Federal Register 8980 Volume 46, Number 17). The drug sponsor had to start showing:

  • Results of preclinical testing
  • The purpose of the studies and tests in humans

Everything started to be wrapped up in the so-called Investigational New Drug Application (IND). This document connects and gathers all the data throughout the long lastly procedure of pre-clinical drug development. The data included in the IND needs to be generated from different sources, and includes efficacy and safety information from in vitro and in vivo (animal models) models. Along Chemistry Manufacturing and Controls (CMC), this document is the foundation of balancing risks and benefits to humans, supporting the initiation of first-in-human studies.

Overall, the IND procedure assures that the efficacy, safety and quality will be met as an investigational drug. Still, these three criteria are a never-ending assessment, even after reaching the market [1].

 Historical perspective

Understanding the anatomo-physiology of organs has always been one of many fundamental questions of Human Medicine. That knowledge underlies the understanding of the molecular and cellular counterparts of homeostasis of organ function and the mechanisms disrupting its normal physiology, which are the basis for the development and design of new and better drugs. Additionally, these aspects are paramount to study in depth the formation of organs, fulfilling the quest for the design of human organs for transplantation purposes. Ultimately, providing chronic organ failure patients with solutions that increases drastically their quality of life.

Consistent research efforts supporting the development of organoids, organized cellular structures in a Petri dish, have more than one century. The precluding steps were taken back in 1907, when Henry Van Peters showed in sponge cells that physical dissociated cell lines could then be spontaneously reorganized generating an organized organism.

The corollary of all the basic research being performed in the fields of Stem cells as led to:

  • The generation of a vascular liver organoid in 2006
  • Proto-organoid of neuronal cells by 2008 (cerebral organoids in 2013)
  • Intestine organoids structures in 2009
  • The first renal organoids conceived from murine cell lines in 2010
  • In 2014, cardiovascular human organoids were generated in research labs, among many other major achievements.

We come this far to have gained the information, knowledge and wisdom to generate a multitude of 3D organoids. In very simple terms, we start by the collection of fibroblast cells from humans, then undifferentiated to Induced Pluripotent Stem Cells (iPSC) and further differentiated into a specific type of Organ (Heart, Liver, Lung, Kidney, CNS, Gastro-Intestinal, you name it).

 

Current trends

Certainly, one out of many practical applications of Organoids is to test new drugs for both safety and efficacy parameters. What are the advantages and capabilities of Organoids in new drug development?

  • Gathering Human-derived data earlier in the R&D process - since human organoids represent human physiology, rather than being a ‘human-like’ or ‘similar’ system;
  • Relatively rapid method - adult stem cell-derived and pluripotent stem cell-derived organoids can be established rapidly and consistently;
  • Process robustness - once established, scale-up is usually possible for large-scale genomic and drug screening activities;
  • Genetic manipulation - most modern genetic engineering tools can be applied to induced pluripotent stem cells or directly to organoid systems;
  • Reaching personalization - induced pluripotent stem cells and organoids can be obtained from individuals and mimic specific phenotypes [2].

 

Preclinical toxicology is a supporting tool to estimate safety therapeutic windows and to provide a general picture on the toxicology profile. Hence, exposing the drug development sponsor to unaware safety and tolerability risks. Organoids is one of the technologies driving the way to better toxicology profiling of drugs before the first-in-humans studies. Namely on:

  • Comprehensive understanding of toxicity mechanisms;
  • Overcoming interspecies variability;
  • Smoother translation of drugs from preclinical to clinical stages

On and on, leading to a stronger prediction of safety events, mitigating risks connected to unexpected side effects. Even supporting the development of biomarkers as surrogate clinical endpoints to a fiduciary safety and tolerability of investigational drugs [3].

Future trends

The industrialization of Organoids in drug development is in its aftermath. Some trends in the near term could eventually encircle the following:

  • In the short-medium term we will certainly move towards complex organoids composed of a multitude of cell types, being closer to full human resemblance, offering the right milieu to test new drugs;
  • The regulatory landscape will be highly supportive of defined standard enabling a consistent, effective and rationale use of this technology;
  • Technology enablement applied to Organoids will foster new analytical methods and capabilities to a leaner drug development approach. Especially when crossing it with:
  • Imaging technologies that will bring forth accurate in situ Pharmacokinetic and Pharmacodynamic insights in a continuous way;
  • Computational and Mathematical modelling that will yield methods to integrate and process in a consistent manner tons of data beyond human capability;
  • Multiomics methodologies (Genomics, Transcriptomics, Metabolomics, Proteomics) for a non-stochastic and unbiased drug discovery path;
  • Other technologies, since no one has a crystal ball to predict the future.

AccelBio Organoids

The AccelBio leitmotif is exCell the patient mission. Our commitment is mirrored in a vertically integrated R&D approach (target validation, hit identification, lead optimization and early ADMET), offering the possibility to streamline drug design and translation via our R&D Quality by Design approach applied to Organoid systems (CNS, Cardiovascular and Kidney).

We would love to hear your views on the topic. Connect and partner with us! Find us through our website and social networks (LinkedIn, Twitter and Instagram).

[1] https://www.fda.gov/files/Promoting-Safe-and-Effective-Drugs-for-100-Years-%28download%29.pdf

[2] https://www.nature.com/articles/s41580-020-0259-3

[3] https://www.nature.com/articles/s41573-022-00633-x

Our Mariana Branco just won the third prize of the AIDFM-CETERA Award for her article "Human multilineage pro-epicardium/foregut organoids support the development of an epicardium/myocardium organoidum" published in Nature Communications. In this work, Mariana and the team have been able to develop human heart organoids that will allow the advancing of knowledge of myocardium-epicardium interactions in healthy or diseased settings and the screening of new drugs of interest.

 

Last week Pedro Silva, President of the Direction, and Bárbara Gomes, AccelBio's CEO, were in Tel Aviv to get to know the Israeli innovation ecosystem.

With meetings with Tel Aviv University (Blavatnik Center for Drug Discovery) and Weizmann Institute of Science (Bina and Yeda), this was an excellent opportunity to learn about different perspectives and methodologies in the area of academic innovation and technology transfer.

We look forward to continuing our collaboration in the future.

In an interview with Nuno de Noronha, Sapo Lifestyle, Bárbara Gomes and Hugo Almeida explained how AccelBio can contribute to the Portuguese biomedical ecosystem.

Please check the interview here: https://lifestyle.sapo.pt/saude/noticias-saude/artigos/accelbio-este-e-o-laboratorio-portugues-que-quer-colocar-farmacos-inovadores-no-mercado

The 3rd CoLABs Annual Meeting was held in Faro, Algarve, and organized by Agência Nacional de Inovação.

During two days we had the pleasure to share AccelBio's activities with other CoLABs, discuss opportunities and, above all, strength this amazing network of Collaborative Laboratories.

Between November 29th and 30th, our Chief Executive Officer Bárbara Gomes has made her way over to Biofit 2022 in Strasbourg to present our capacities.

During the event, Nuno Prego Ramos, CEO of our associate CellmAbs, talked about IP licensing issues for start-up companies and shared the strategies of the company to overcome these issues.
This talk was part of the kick –off meeting of LEAP-Bio project, funded by European Commission. LEAP-BIO aims to develop an early-stage focused IP licensing intermediary service for biopharma SMEs and startup companies and is co-lead by our associate Instituto de Medicina Molecular.

Joana Branco and Bárbara Gomes kicked-off the week at BIO-Europe 2022 in Leipzig, Germany.
BIO-Europe is the place to meet the biotech world all under one roof to discover the latest innovations and advance the medicines of tomorrow while discussing new partnering opportunities.

 

On September 19th and 20th, Bárbara Gomes, AccelBio's CEO, participated in BIOMEET 2022, the annual meeting of the Biotechnology sector, organized by P-BIO and aligned with the celebrations of the European Biotechnology Week 2022.

During the event, Portugal has shown its strength as a biotech and innovation hub.

[et_pb_section][et_pb_row][et_pb_column type="4_4"][et_pb_text]On May 19th, we had the pleasure to present the CoLAB AccelBio to the Comission on Social Issues and Cohesion of the Saxon State Parliament, in a visit promoted by the Health Cluster Portugal.[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

On July 5th, we had the pleasure to present the CoLAB AccelBio to the iMM community.

July 22nd, 2022
Two of our associates - LiMM Therapeutics and BSIM Therapeutics - were considered two of the most promising biotech companies in Portugal by Labiotech.eu 

For more info: https://www.labiotech.eu/best-biotech/biotech-portugal-companies/

Call Open
The AccelBio Open Call pairs academic teams with AccelBio's translational and computational experts for 18 months, to move drug discovery projects with a validated, druggable target to the next stage of development and turn promising science into assets ready for industry.
Many promising academic projects stall between discovery and development because they lack translational data, industry-standard methods or a development strategy. Through this Open Call;
AccelBio aims to:
Close defined translational gaps in promising academic drug discovery projects;
Move assets to the next de-risked value inflection point in drug discovery;
Introduce industry practices and standards into academic laboratories;
Build the capacity of research teams to bring assets into the drug development value chain.
Each selected project is developed in close collaboration between AccelBio and the host lab, following a workplan built together after selection. Two projects will be selected.
This Programme is open to Portuguese public or non-profit legal entities (universities, research centres, hospitals) that own or co-own the project’s assets. Assets do not need to be protected by a patent application.
Eligible Proposals must be in therapeutic drug discovery for human health and address a clearly defined unmet clinical need, in any therapeutic area.
As a minimum, projects must have a validated, druggable target: evidence linking the target to the disease, and evidence that it can be modulated by the proposed modality.
Eligible modalities are small molecules, peptides and advanced therapy medicinal products (ATMPs), namely gene therapies or cell therapies.
The following Projects are not eligible for this Call:
Projects without a validated target, or without evidence that the target is druggable, including target discovery, hypothesis generation or fundamental research projects;
Projects whose key remaining activities fall mainly within downstream drug development (e.g. GLP toxicology, GMP manufacturing, clinical trials);
Projects that mainly seek funding for staff, running costs or research activities;
Projects without the possibility of generating or strengthening protectable IP;
Projects on diagnostic tools, medical devices, biomaterials or digital health tools.
The evaluation process will consist in 3 phases:
Eligibility check: AccelBio checks each Proposal against the Rules for Participation, including the minimum entry point (validated, druggable target);
Remote evaluation: each eligible Proposal is scored by up to three (3) members of the Evaluation Committee. The evaluation criteria, each with its own weight, are:
SCIENTIFIC QUALITY AND TARGET VALIDATION: Quality of the science and preliminary data, strength of target validation and druggability, unmet clinical need, novelty (30%);
TRANSLATIONAL GAP AND FIT: A clearly defined translational gap that AccelBio can address (20%);
ACHIEVABLE VALUE INFLECTION POINT: A defined milestone, reachable within 18 months, that moves the asset to the next stage of drug discovery (20%);
HOST LAB COMMITMENT: Expertise of the team and resources committed (15%);
IP AND PARTNERING POTENTIAL: Potential to generate or strengthen protectable IP and route to licensing, partnering or company creation (15%).
Interview: Shortlisted applicants present their project remotely to the Evaluation Committee.
Full details on the evaluation process can be found in the document Guidelines for Evaluation.
The Open Call does not provide any monetary contribution. Each selected project receives, for 18 months:
Technical Support: Each project is paired with a translational researcher who collaborates with the Project Leader and team to formulate a Valorisation Plan. This plan guides the execution of proposed activities, such as validation and testing, prototyping, and business strategy design.
Translational advisory support: A dedicated AccelBio translational scientist who reviews the evidence, advises on experimental design and assay quality, analyses data with the team, and builds the workplan and Valorisation Plan with the Project Leader.
Selected computational work: Virtual screening and hit prioritisation, structure-based design and in silico ADMET, and PK/PD modelling.
Business development and partnering: Target Product Profile, market and competitive analysis, IP strategy, business case, and introductions to industry, investors and AccelBio’s associates.
This collaborative framework ensures that selected projects are scientifically robust, market-aligned, and strategically positioned for future development and investment.
For further information, please read the Rules for application and the Evaluation Guide or contact geral@accelbio.pt
Aplication Period
March 15th - April 30th
Pre-selection Phase
May
Presentation and Interview
June
Communication of Results
July
Start of the project
September

Previous Editions​

Open Call 2024

Open Date
March 2, 2024
Close Date
May 2, 2025
Total number of applicants​
26
Number of approved applications​
2
Selected projects
COMASLINK
Project Leader: Sandra Vaz
Beneficiary Institution: AIDFM - Associação para Investigação e Desenvolvimento da Faculdade de Medicina
FATLOSS
Project Leader: Luisa Figueiredo
Beneficiary Institution: GiMM - Gulbenkian Institute for Molecular Medicine

Open Call 2026 Application Form

Form Calls

(only applications following the approved AccelBio Open Call 2026 Application template will be eligible for evaluation)

All fields are mandatory.
In case multiple applications are submitted for the same project proposal, only the latest submitted proposal will be considered for evaluation.

By submitting your personal information you are automatically agreeing with our Terms & Conditions and Privacy Policy.

Ready To Get Started?

Sign up with your email address to receive news and updates.
By subscribing to receive news and updates you are automatically agreeing with our Terms & Conditions and Privacy Policy.
Subscription Form